PDCD1 and hepatocellular carcinoma: (2023) conducted a preliminary study to assess the feasibility of utilizing a CD133-specific CAR-T cell system to deliver locally PD-1 blocking scFv as a monotherapy for advanced hepatocellular carcinoma (HCC).